Phase 1 trial of siltuximab for antibody-mediated rejection after lung transplant
Official title: A Phase 1 Clinical Trial of Siltuximab for the Treatment of Antibody-Mediated Rejection after Lung Transplantation
Funded at Utah State Higher Education System--University of Utah · NIH-11419647 · Data updated 2026-11-12
A early-stage study tests whether siltuximab can help people who have antibody-mediated rejection after lung transplantation.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Utah State Higher Education System--University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project start | September 15, 2023 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $596,825 |
| NIH project number | 5R33HL169189-04 |
| Project ID | NIH-11419647 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with antibody-mediated rejection following lung transplant who meet study criteria.
✕Less likely to help
Patients without AMR or those who cannot tolerate the study treatment may not benefit.
What this research studies
This project tests a targeted therapy for people who have lung transplants and develop antibody-mediated rejection (AMR), a major cause of problems and poorer survival. The study builds on knowledge that IL-6 helps drive immune responses and may worsen rejection, using siltuximab to block IL-6 signaling. It is a Phase 1 trial focused on safety and dosing with careful monitoring of immune responses and early signals of effectiveness. Participants will be adults who have AMR after lung transplant and will receive the study drug under close medical supervision.
Why it matters
Potential benefit: If successful, the treatment could improve graft function and survival by reducing harmful immune responses.
How similar studies have gone: Other immune-targeted approaches in transplant rejection have shown potential, but this specific IL-6 blocker approach for lung AMR is exploratory.
Where this research is happening
-
Utah State Higher Education System--University of Utah
Salt Lake City, United States Active
Researchers
- Principal investigator: Hachem, Ramsey — Utah State Higher Education System--University of Utah
- Study coordinator: Hachem, Ramsey
Related research
Other NIH-funded projects on the same topics.
-
Targeted delivery of immune-suppressing agents to the lung graft to prevent rejection
A study at Northwestern University will test a new, targeted approach to prevent lung transplant rejection by delivering immune-suppressing drugs directly to the graft while blocking early signals that trigger rejection.
-
Siltuximab for antibody-mediated rejection after lung transplant
This trial gives siltuximab to people with antibody-mediated rejection after a lung transplant to try to control the immune response harming the new lung.
-
Role of plasma cells in chronic rejection after lung transplantation
This research looks at how certain immune cells called plasma cells may drive chronic rejection in people who have had lung transplants and how this could lead to new ways to protect the transplant.
-
Non-invasive infection detection after lung transplant
A non-invasive blood test using phage-based signals could help doctors detect lung infections early in people who have had a lung transplant.
-
Investigating the role of plasma cells in lung transplant rejection
This study is looking at how certain immune cells, called plasma cells, might play a role in lung transplant rejection, especially for patients dealing with bronchiolitis obliterans syndrome, and it hopes to find new ways to help improve the success of lung transplants.
-
Sending anti-rejection medicine directly to blood vessels in transplanted lungs
This project tests tiny drug carriers that deliver anti-rejection medicine straight to the blood vessels of transplanted lungs to help people who receive lung transplants.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.